Keywords
mechanical circulatory support - thrombosis - bleeding - heparin - anticoagulation
Introduction
Both bleeding and ischaemic complications are frequent in patients on mechanical circulatory
support (MCS). A meta-analysis of 1,866 adult patients with cardiogenic shock treated
with extracorporeal membrane oxygenation (ECMO) reported major or significant bleeding
in 40.8% of patients, lower limb ischaemia in 16.9% and stroke in 5.9% of patients.[1] In patients receiving MCS, the artificial surface of the circuit activates the contact
pathway of the coagulation cascade and, in combination with the inflammatory response,
is an ongoing driver of thrombosis ([Fig. 1]). At the same time, over-anticoagulation, low platelet count and/or acquired platelet
dysfunction due to loss of platelet receptors through the MCS and acquired von Willebrand
syndrome (AVWS) all contribute to an increased risk of bleeding. AVWS is frequent
with ECMO and can greatly exacerbate bleeding.
Fig. 1 Etiology of thrombosis and bleeding in patients on mechanical circulatory support
and tests available to identify these risks. Contact of blood with the artificial
circuit results in activation of coagulation, while platelet activation occurs due
to the foreign surface and high shear flow conditions. Activation of coagulation and
platelet aggregation result in platelet thrombus formation. Meanwhile, MCS particularly
with continuous (as opposed to pulsatile) flow leads to cleavage of HMWM of vWF and
development of AVWS, increasing the susceptibility to bleeding. Endogenous fibrinolysis,
mediated predominantly by tissue-activated plasminogen activator (t-PA), plasminogen
activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI),
is responsible for prevention of lasting thrombotic occlusion and when enhanced can
increase bleeding risk. Conventional tests to assess UFH shown in blue rectangles, more novel tests of haemostasis
and fibrinolysis shown in green rectangles. AVWS, acquired von Willebrand syndrome; HMWM, high-molecular-weight multimer; MCS,
mechanical circulatory support; UFH, unfractionated heparin; vWF, von Willebrand factor.
Maintaining optimal haemostasis and preventing significant bleeding and thrombosis
are key aspects of managing patients receiving ECMO. Anticoagulation is essential
for left-sided support to prevent thrombotic complications and reduce the risk of
systemic embolism, including stroke or limb ischaemia.[2] This is usually achieved with intravenous unfractionated heparin (UFH),[2] or the direct thrombin inhibitors bivalirudin or argatroban when UFH is contraindicated,
such as in the case of allergy to UFH/heparin-induced thrombocytopenia (HIT), or in
patients with severe acute antithrombin (AT) deficiency when treatment with AT concentrate
is also an option. There are no randomised controlled trials to guide anticoagulation
targets in patients on ECMO.
Maintaining optimal anticoagulation is challenging, as monitoring of UFH can be difficult
in patients on MCS[2] and the ideal strategy for monitoring remains unknown. In addition to assessing
the effect of anticoagulation, it is also important to assess the overall haemostatic
profile, to assess bleeding and thrombosis risk ([Fig. 1]). Platelets play a major role in both primary and secondary haemostasis, and thrombocytopenia
and/or impaired platelet function can contribute to the excess bleeding risk.
Depending on the centre, the method used for monitoring UFH varies, and may relate
to the availability of the tests, as well as to clinician preference. The most commonly
used tests include the activated clotting time (ACT), activated partial thromboplastin
time (aPTT) and heparin levels as measured by anti-Xa level. Furthermore, to assess
haemostasis, most centres offering ECMO routinely check prothrombin time (PT) and
fibrinogen.[2] Additionally, measurement of AT level and thromboelastography (TEG), as an assessment
of global haemostasis, are reported to be used variably, or on an ‘as-needed’ basis.
Newer tests are also available, but their role is often not well understood.
There are currently no guidelines regarding the optimal assessment of patients on
ECMO. The aim of this review is to present available tests to assess the anticoagulant
intensity of UFH and other haemostatic tests to predict bleeding and thrombosis, to
provide guidance to practicing clinicians.
We performed a literature search using the MEDLINE/PubMed database, including articles
published online from inception until January 2020. The search strategy is described
in Appendix A. As this is a narrative review, included articles were selected based on the authors'
joint subjective determination of relevance to the overall theme of this article and
the most pertinent articles informing clinical practice were referenced.
Assessing Anticoagulant Effect
Assessing Anticoagulant Effect
The optimal anticoagulant monitoring strategy for UFH in patients receiving ECMO is
undefined ([Table 1]). Overall, the dose of UFH best correlates with the anti-Xa level; however, whether
levels relate to bleeding and thrombosis is not established in large studies. A study
in paediatric ECMO patients reported poor correlation between UFH dose and either
anti-Xa level (ρ = 0.1, p < 0.0001) or aPTT (ρ = 0.26, p < 0.0001). Anti-Xa level and aPTT were weakly correlated (ρ = 0.38, p < 0.0001) and neither was related to survival or haemorrhagic and thrombotic complications.[3]
Table 1
Tests available to monitor anticoagulation with unfractionated heparin
|
Test
|
Advantages
|
Disadvantages
|
|
ACT
|
• Point-of-care test
• Rapid to perform
• Whole blood test
|
• No clear validation in ECMO
• Affected by haemodilution, hypofibrinogenemia, thrombocytopenia, liver failure,
inflammation, lupus anticoagulant and consumptive coagulopathy
• Used alone may lead to suboptimal anticoagulation with ECMO
|
|
aPTT
|
• Point-of-care test available (not routinely)
• Best predictor of bleeding
• Relatively inexpensive
|
• Often central laboratory: time delay
• High variation between reagents and laboratories
• Affected by many biologic factors, often disturbed in critically ill patients
• Range based on anti-Xa
|
|
Anti-Xa
|
• Considered gold standard for assessing heparin effect
• Good correlation with heparin dose
• Unaffected by presence of lupus anticoagulant, liver disease or consumptive coagulopathy
|
• Expensive
• Difficult to automate
• Not universally available
• Not point-of-care; central laboratory required: time delay
|
Abbreviations: ACT, activated clotting time; anti-Xa, anti-factor Xa; aPTT, activated
partial thromboplastin time; ECMO, extracorporeal membrane oxygenation.
Activated Clotting Time
In the critical care setting, UFH dose has previously been titrated to the measurement
of the ACT, a widely available point-of-care assay.[2] Performed on whole blood after addition of an activator (e.g., kaolin), it provides
a rapid assessment of the adequacy of anticoagulation when high-dose UFH is used.
However, it may not provide an accurate measure of UFH anticoagulant effect as a result
of various confounding factors which are more marked in critically ill patients, including
liver failure, haemodilution, thrombocytopenia, hypothermia, extreme fibrinogen levels,
inflammation, lupus anticoagulant and consumptive coagulopathy.[4] Although routinely used, its effectiveness to guide anticoagulation in this patient
group has never been prospectively studied. Numerous reports indicate that monitoring
UFH with ACT alone leads to suboptimal anticoagulation during MCS. In 46 adult patients
on veno-arterial (VA) or veno-venous (VV) ECMO, heparin dose correlated better with
aPTT than ACT.[5] In paediatric patients receiving ECMO with comparable ACT levels, a 0.01 IU/mL decrease
in anti-Xa level was shown to increase the risk of circuit thrombosis by 5%.[6] In a retrospective analysis of 604 children on ECMO monitored with ACT in the range
180 to 220 seconds, there was an improved survival with increased heparin dose and
ACT did not correlate with heparin dose, implying that ACT may be too insensitive
to guide systemic anticoagulation.[7]
Activated Partial Thromboplastin Time
Although aPTT is a commonly-used, inexpensive and readily available test, it may not
provide an accurate measure of the amount of UFH present because of various confounding
factors including both pre-analytical and analytical variables. The aPTT is measured
by adding a surface activator and calcium to citrated plasma. Both laboratory and
point-of-care aPTT tests are available. In the intensive care setting, aPTT correlates
better with heparin concentration than ACT, although the optimal aPTT target range
and the correlation between aPTT and bleeding risk in patients on ECMO remains unclear.[5]
[8] Both laboratory and point-of-care aPTT tests correlate poorly with heparin anti-Xa
levels. Although several studies have shown that elevated aPTT level is a better predictor
of bleeding than anti-Xa level. In a study of 539 adult in-patients treated with UFH,
discordant aPTT and anti-Xa values were found in 42% of paired samples.[9] In these patients, a disproportionately higher aPTT was associated with increased
bleeding (9 vs. 3%, p = 0.03) and 30-day mortality (14 vs. 5%, p = 0.02). In a prospective study of 202 paediatric patients undergoing cardiac surgery,
an elevated aPTT, but not anti-Xa level, was associated with bleeding.[10] In a retrospective analysis of 149 adult patients on ECMO (111 VA and 38 VV), higher
aPTT levels were independently associated with bleeding.[11] These findings may be a reflection of intrinsic coagulation abnormalities rather
than the direct effect of UFH.
There is significant variability in aPTT readings between laboratories, different
instruments and even between reagents. The American College of Chest Physicians recommends
the determination of aPTT goal ranges for individual institutions based on heparin
(anti-Xa) levels, indicating that heparin level monitoring may be a superior approach.[12]
Anti-Factor Xa Level
The anti-Xa assay evaluates the dose of heparin available in the circulation and may
be considered a surrogate measurement of the overall anticoagulant activity of UFH.
The assay measures the ability of a patient's plasma to inhibit exogenous added factor
Xa (FXa), hydrolysing its synthetic substrate (chromogenic assay) or the anti-Xa activity
is measured by performing an aPTT-based FX assay on each dilution without exogenous
FXa (clotting-based assay).
Heparin anti-Xa assay that does not contain exogenous AT may give a more accurate
estimation of anticoagulation in plasma, thus reflecting the in vivo UFH effect for
the specific patient.[13] However, it may not detect all the heparin present in that sample. Some chromogenic
anti-Xa assays involve the addition of exogenous AT, which may increase the measured
anti-Xa activity, and others that do not add exogenous AT, and the latter maybe considered
a more physiological assessment.[14] However, although anti-Xa assays with added AT trend higher than those without,
a recent paper found a good correlation between the two types of anti-Xa platforms
in paediatric patients treated with low-molecular-weight heparin even when the AT
activity was <70%.[15]
However, while the anti-Xa level is a direct measure of heparin effect, it does not
reflect the overall haemostatic status, which may depend on the amount of thrombin/AT
and pro-coagulant drivers. It is an expensive test and not widely available. However,
unlike aPTT, anti-Xa levels are not affected by the presence of lupus anticoagulant,
liver disease or consumptive coagulopathy.
Small case series in paediatric patients suggest that anti-Xa levels correlate better
with heparin dosing, and probably the overall anticoagulation state during ECMO, than
does ACT or a combination of ACT and aPTT.[16]
[17]
[18] Small retrospective studies demonstrated that the anti-Xa level was predictive of
circuit thrombosis in paediatric[6] and adult patients[19] on ECMO, where for every unit decrease in anti-Xa level, there was a sevenfold increase
in deep venous thrombosis.[19] However, some studies indicate that for the assessment of bleeding risk, aPTT is
superior to anti-Xa for monitoring UFH in paediatric patients undergoing cardiac surgery,[10] and in adult patients receiving ECMO.[20] This could be due the fact that aPTT is reflective of both heparin and the other
intrinsic coagulation factors, whereas anti-Xa levels indicate only the heparin levels
present. In a retrospective single-centre study of 34 adults on ECMO, in whom heparin
was monitored by anti-Xa and/or aPTT, some 15% of patients experienced a major thrombotic
event and 27% experienced a haemorrhagic event.[20] The anti-Xa assay better correlated with weight-based heparin dose than aPTT. Low
anti-Xa values were predictive of thrombosis, whereas high aPTT values were predictive
of bleeding. In a prospective study of 202 paediatric patients treated with UFH after
cardiac surgery, in those who experienced bleeding events, the highest aPTT and corresponding
anti-Xa for the 24 hours before bleeding events were used to assess the predictive
value of these tests for bleeding. While there was a moderate correlation between
aPTT and anti-Xa, aPTT >150 seconds was significantly related to bleeding (odds ratio:
1.71 per 10-second increase in aPTT; 95% confidence interval: 1.21–2.42; p = 0.003), whereas anti-Xa was not associated with bleeding.[10] Therefore, a combination of anti-Xa and aPTT monitoring approach to detect thrombotic
and bleeding risk may be preferable to either alone.
Antithrombin III Level and Anticoagulant Effect of UFH
AT is essential as a cofactor for UFH to exert its anticoagulant effect. AT deficiency
may result in inadequate anticoagulation with UFH at usual doses. Acquired AT deficiency
is common in acutely unwell patients due to either decreased production or increased
consumption, especially with MCS. While a consensus definition is lacking, ‘heparin
resistance’ (HR) refers to the requirement of very high doses of heparin usually in
excess of 35,000 units within a 24-hour period to maintain the anti-Xa level or aPTT
within the therapeutic range.[21] The prevalence of HR with extracorporeal circuits was originally derived from large
case series of patients undergoing cardiopulmonary bypass, including those supported
with intra-aortic balloon pumps. In these studies, the prevalence of HR was around
20%,[22]
[23]
[24] depending on the definition of HR used, and was associated with adverse outcomes.[25] A large retrospective study in paediatric patients on ECMO showed that subtherapeutic
aPTT was associated with increased mortality and increased heparin dosing conferred
a survival advantage.[7] However, a more recent small study of 69 neonatal and paediatric ECMO patients showed
that neither dose of UFH nor time at therapeutic anti-Xa or aPTT levels affected the
risk of bleeding or survival.[3] The prevalence of HR is reported in only two studies of patients on ECMO. In one
study of 67 adult patients on VA or VV ECMO, half the patients had HR,[21] and there was no apparent relationship between HR and thrombotic or bleeding complications.[21] A recent study of 81 adult patients with COVID-19 receiving VV ECMO and renal replacement
therapy indicated that all patients met the criteria for HR.[26] The Extracorporeal Life Support Organization (ELSO) recommends maintaining AT levels
within the normal range (80–120% of control) during ECMO,[13] although AT assays are not readily available in all hospitals. Low AT can be treated
by giving fresh frozen plasma, cryoprecipitate, human plasma-derived AT or recombinant
AT concentrate, although the latter is expensive. Although not formally evaluated
in patients supported with ECMO, AT concentrate is preferable to cryoprecipitate or
fresh frozen plasma, since the latter carries the potential risk of transfusion-transmitted
infections and contains only a small concentration of AT unit per volume of plasma
(fresh frozen plasma contains only 1 U/mL of AT), necessitating large volumes to normalise
AT levels, which could lead to volume overload or transfusion-related acute lung injury.[27]
Low AT may be a particular problem in neonates, who have a physiologic deficiency
of AT, with levels as low as 40% of the adult range and this can be exacerbated by
sepsis and MCS. In adults, there are no studies showing the clear benefit of closely
monitoring and maintaining the AT level within the recommended range, with recent
data suggesting that AT supplementation may not decrease heparin requirements, not
diminish the incidence of bleeding and/or thrombosis in adult patients on ECMO.[28]
Tests to Assess the Haemostatic State of Patients on MCS
Tests to Assess the Haemostatic State of Patients on MCS
Thromboelastography and Thromboelastometry
Both TEG and rotational thromboelastometry (ROTEM) provide information on the characteristics
of clot produced ex vivo under low shear conditions. As the clot starts to form, changes
in impedance reflect the dynamics of clot formation, viscoelastic clot strength and
clot lysis. Both are point-of-care tests and utilise either native blood, which must
be tested immediately, or citrated whole blood, which is stable for up to 2 hours
at room temperature and requires re-calcification prior to analysis.
Drawbacks include the necessity for staff training and inter-operator variability
with TEG, which unlike ROTEM, is not automated, and it can take up to 2 hours to obtain
results. Use of activators of coagulation such as tissue factor can accelerate the
test producing results in 15 minutes, although this compromises the physiological
relevance of the test.
Both TEG and ROTEM are used in cardiopulmonary bypass to assess haemostasis and guide
blood transfusion requirements. Hyperfibrinolysis based on the manufacturers' definitions
of maximum lysis >15% in the ROTEM or Lysis30 >8% in the TEG, a measurement derived
from the reduction of clot firmness over time, has been shown to be associated with
increased bleeding. However, data supporting their usefulness in the setting of ECMO
are less robust. A retrospective evaluation of 27 paediatric patients on MCS, predominantly
VA ECMO, showed a weak correlation between TEG variables and aPTT, and between TEG
and ACT, with a stronger correlation between TEG (maximum amplitude, MA) and platelet
count.[29] A retrospective analysis of prospective data to assess UFH effect in adults on VV
or VA ECMO showed a weak correlation between ROTEM clotting time and aPTT, with no
agreement between the directional changes of aPTT and ROTEM clotting time results
on successive days.[30]
Small studies showed that a reduced maximum clot firmness (MCF) was predictive of
bleeding in adult patients on ECMO, while a low MCF was observed in only 17% of non-bleeders.[31] In 23 patients initiated on ECMO and 24 on ventricular assist (Berlin Heart Excor),
MCF was predictive of bleeding and 30-day mortality.[32] In 57 adult patients on VV ECMO, clotting time, but not MCF, correlated with severity
of bleeding.[33] In terms of transfusion requirements, a prospective trial of 42 adult patients on
VV ECMO randomised to TEG-guided or aPTT-guided anticoagulation protocols showed no
significant difference in bleeding or thrombotic events.[34] Furthermore, a study in 57 adult patients showed that VV ECMO leads to a continuous
increase in clotting time and a decrease in MCF the longer the ECMO lasts, but addition
of ROTEM to aPTT or fibrinogen measurement did not aid the prediction of bleeding.[33] The role of these viscoelastic tests in assessing thrombosis is even weaker. In
a retrospective chart review of 30 paediatric patients on VA or VV ECMO, a TEG R-time
greater than 17.85 minutes and anti-Xa activity greater than 0.25 IU/mL were independent
predictors of thrombosis.[35] However, a meta-analysis including nine studies of paediatric patients on ECMO concluded
that none of the measures of heparin anticoagulation, including TEG-R, correlated
with either bleeding or thrombotic episodes.[36]
Thus, there are limited data indicating a role for TEG/ROTEM in predicting bleeding
and possibly to guide anticoagulation and transfusion in patients on MCS, but not
in predicting thrombotic complications.
Thrombin Generation
Thrombin (human activated coagulation factor II) is one of the key players in the
haemostatic system. Activation of both the extrinsic (tissue factor) and intrinsic
(contact) coagulation pathways results in conversion of prothrombin to thrombin via
FXa, resulting in fibrin formation. Whereas most tests focus on a particular part
of the thrombotic process (e.g., d-dimer levels on fibrin degradation, aPTT on the
intrinsic pathway), thrombin generation (TG) provides a more global assessment of
coagulation which assesses the capacity of blood to generate thrombin after stimulating
the coagulation pathway with exogenous tissue factor. Specifically, lag time (time
to minimum thrombin formation), peak height (maximum thrombin concentration) and endogenous
thrombin potential (ETP), which is the total amount of thrombin generated (area under
the curve [AUC]), are reported. The greater the TG, the greater the potential for
thrombosis and the less for bleeding. TG can be assessed in platelet-poor, platelet-free
or platelet-rich plasma, where the latter enables the investigation of interaction
between platelets and coagulation factors, which closely mimics in vivo conditions.
An advantage of the TG assay is that it measures the full potential of the plasma
sample to generate thrombin, whereas conventional coagulation tests (PT, aPTT) terminate
with fibrin clot formation when 95% of thrombin is yet to be formed. However, TG is
an expensive specialised laboratory test, not rapidly available in the acute setting
and more widely used in research. Automated tests such as the Thrombinoscope version
of the calibrated automated thrombogram are becoming available, but data are scarce.
TG is mainly used to asses congenital or acquired bleeding disorders related to haemostasis,
or to assess antithrombotic treatment. Outwith the setting of ECMO, several retrospective
and prospective observational studies have shown a strong correlation between high
ETP and the occurrence of venous thrombosis,[37]
[38]
[39] although data on ECMO patients are sparse. In a small study, peak TG and ETP were
significantly higher in samples from 20 patients on ECMO compared with control plasma.[40] However, although half the cohort experienced a pulmonary embolism, there were no
significant differences in lag time, peak TG, or ETP between patients with and without
pulmonary embolism.
Although there is a strong correlation between increased TG and the occurrence of
venous thrombosis,[41] a relationship with arterial thrombosis has not been established. Reduced TG in
patients on cardiopulmonary bypass is related to peri-operative bleeding.[42] A small study assessing TG in adult patients on VA ECMO showed an increased peak
TG, and an increased ETP compared with controls, indicative of a pro-coagulant profile.[40] Tests of TG may therefore have a role in the prediction of both bleeding and thrombosis,
but convincing clinical data in the setting of ECMO are lacking.
D-dimer
D-dimer is a fibrin degradation product, produced as a result of fibrin formation
and degradation. Although marked elevations may indicate the presence of venous thromboembolism
or disseminated intravascular coagulation, D-dimer is a non-specific marker that is
elevated in other conditions including sepsis. Individual D-dimer levels are not helpful
in patients on ECMO, but daily measurement is recommended since an increase in D-dimer
in the absence of other explaining pathology during ECMO therapy may reflect coagulation
activity within the membrane oxygenator,[43] and decrease after circuit exchange.[44] Rising levels of D-dimer are usually considered in the context of other markers,
such as a rising plasma-free haemoglobin and falling fibrinogen, which together should
prompt the need for urgent consideration of circuit change.
Assessment of Platelet Count and Platelet Function
Regular assessment of platelet count is essential, with vigilance for the occurrence
of HIT, which occurs in some 4 to 7% of ECMO patients.[45] A low platelet count or a fall in platelet count should prompt consideration of
HIT and various scores are available to gauge the likelihood of this.[46] In individuals with suspected HIT, heparin should be discontinued and replaced with
a non-heparin anticoagulant, while awaiting laboratory confirmation of HIT, which
is initially assessed with enzyme-linked immunosorbent assay for antiplatelet factor
4 antibodies.
Light Transmission Aggregometry and Multiple Electrode Aggregometry
Light transmission aggregometry (LTA) is considered the gold standard to assess platelet
aggregation. However, it involves multiple steps and specialist laboratory expertise.
It utilises anticoagulated platelet-rich plasma to which various agonists are added
to stimulate platelet aggregation, including collagen, thrombin and thromboxane A2.
Multiple electrode aggregometry (MEA) is a later derivative of impedance aggregometry,
which employs anticoagulated whole blood, can be used as a point-of-care technique
and has been shown to predict bleeding in patients undergoing cardiopulmonary bypass.[47]
In an experimental artificial circuit perfused with human blood, initiation of mechanical
circulation was associated with reduction in platelet count and platelet aggregation
as measured using LTA and MEA.[48]
There are small studies showing reduced platelet aggregation in adult patients on
ECMO.[49] However, assessment of platelet function in patients on ECMO can be challenging,
since it can be compounded by the presence of thrombocytopenia, present in some 25%
of VV and 23% of VA ECMO patients, which begins within 2 to 3 days and is not related
to duration of ECMO.[50] A recent meta-analysis of 21 studies evaluating patients on ECMO revealed impaired
platelet function, predominantly impaired platelet aggregation, in several studies,
and a few studies also demonstrated reduced platelet adhesion and activation, including
granule secretion.[50] A meta-analysis of three paediatric ECMO studies demonstrated reduced platelet function
as assessed using platelet aggregometry, flow cytometry and TEG-platelet mapping,
which in two studies was irreversible by platelet transfusion.[51] However, this should be interpreted with caution since another recent small study
of 33 adults on VA or VV ECMO showed that both platelet count and platelet aggregation
were reduced on ECMO, but when aggregation was assessed relative to platelet count,
this did not differ from that of healthy controls.[52] Furthermore, mild haemolysis is common in patients on ECMO, with severe haemolysis
in 2 to 20% of patients, which can further compound platelet function analysis performed
using whole blood.[53]
If the LTA or MEA shows significant platelet dysfunction in the presence of major
bleeding, antiplatelet should be withheld and consideration should be given to platelet
transfusion, even in the presence of normal platelet count. In the case of minor bleeding,
the risk of withholding antiplatelet treatment should be balanced against the risk
of bleeding. If the bleeding risk exceeds ischaemic risk, antiplatelet therapy should
be withheld until the bleeding settles. If the thrombosis risk is high, antiplatelet
therapy should be continued and tranexamic acid administered for 24 to 48 hours.
Role of von Willebrand Factor in Haemostasis
von Willebrand Factor (vWF) is a high-molecular-weight multimer (HMWM), synthesised
and released by endothelial cells. It plays a crucial role in platelet–subendothelium
adhesion and platelet–platelet interaction, and functions as a carrier protein for
coagulation factor VIII. vWF alters from an irregularly coiled to an extended thread-like
state in the transition from shear to elongational flow at sites of haemostasis and
thrombosis. Transition from pulsatile to continuous blood flow, as seen in patients
with continuous-flow MCS, leads to cleavage of large vWF multimers into monomers by
the matrix metalloproteinase ADAMTS-13. Once cleaved, lower-molecular-weight multimers
lose their affinity for binding platelets, increasing the susceptibility to bleeding.
This imbalance between degradation induced by shear stress and the endothelial release
of new vWF triggered by pulsatile flow during MCS results in overall reduction in
HMWM, leading to device-induced AVWS, characterised by bleeding mainly from the mucosal
surfaces, including gastrointestinal bleeding.[54] The high shear in MCS appears to cause shedding of the platelet glycoproteins Ib
(GPIb)/IX and VI, reducing vWF binding on the platelet surface and increasing the
propensity for bleeding.[55]
The diagnosis of AVWS is made by detecting abnormally low vWF activity in relation
to vWF antigen (vWF:Ag) levels, reflected in a deficiency of HMWM on gel electrophoresis.
Although the latter is the gold standard for diagnosing AVWS, this is generally not
readily available, and most centres use the ristocetin cofactor assay (vWF:RCo) to
assess vWF activity in relation to vWF:Ag. The normal vWF:RCo/vWF:Ag ratio is >0.7,
and a ratio of <0.6–0.7 indicates a loss of HMWM and AVWS. Although assessment of
vWF:RCo with platelet aggregometry has been regarded as the ‘gold standard’, this
demonstrates high variability and relatively low sensitivity for AVWS. Automated tests
for vWF:RCo using turbidimetry or chemiluminescence have greatly improved precision,
with markedly reduced coefficients of variation.[56] Other automated tests include the vWF:GPIbR in which platelets are replaced with
latex beads coated with recombinant wild-type GPIb and the vWF:Ab test which uses
polystyrene beads coated with monoclonal antibody directed against the GPIb-binding
A1 domain of vWF.[56] These tests may eventually replace the vWF:RCo performed by aggregometry in many
laboratories. To date, there are no point-of-care tests specifically for AVWS especially
in the setting of MCS, but adaptations of the platelet function analyser and viscoelastic
tests may hold promise (vide infra).
There is evidence that use of continuous-flow mechanical support devices and ECMO
leads to substantial reduction in HMWM of vWF and AVWS-related gastrointestinal bleeding.[54]
[57] Indeed, the permanent high shear stress and continuous blood flow not only induce
proteolysis of HMWMs, but also result in platelet inhibition and reorganisation of
endothelial cells, particularly in the blood vessels of the gastrointestinal tract,
leading to gastrointestinal dysplasia and subsequently bleeding.[57]
[58] ECMO is generally associated with loss of HMWMs within 24 hours of treatment, with
rapid reversal after withdrawal of MCS.[57] In more than 200 patients on long-term pulsatile and continuous-flow MCS, development
of AVWS, vWF:Ag and vWF:RCo levels was predictive of bleeding.[59] The incidence of bleeding is significantly higher with non-pulsatile, continuous-flow
assist devices than that with pulsatile-flow devices. Even using the same non-pulsatile
device (ex vivo ECMO circuit), lowering the flow rate may enhance the loss of HMWMs.[60] Importantly, patients supported with the latest generation left ventricular assist
devices (lower pump speed, different textured interior surfaces, physiological pulsatile
flow) had more intact HMWMs and higher vWF activity compared with patients treated
with older devices.[61]
Possible Future Monitoring Approaches
Possible Future Monitoring Approaches
Point-of-Care Tests to Assess AVWS
Although not evaluated in the setting of MCS, the PFA-100 appears to be a good screening
test for von Willebrand disease (vWD), with high sensitivity. A study in 41 paediatric
outpatients showed that prolonged closure time with the collagen/adenosine diphosphate
(ADP) cartridge had an overall sensitivity of 90% to detect vWD.[62] Specifically, all patients with type 2 or 3 vWD had prolonged PFA-100 closure times
with both cartridge types, whereas amongst those with type 1 vWD, 83% had prolonged
closure times with the collagen/ADP cartridge and 79% with collagen/epinephrine. A
recent review confirms that the PFA-100/200 can be used in urgent situations to exclude
the presence of AVWS with high sensitivity if closure time is normal, with a negative
predictive value (NPV) >99%,[63] although validation specifically in the setting of ECMO is lacking. However, a prolonged
closure time in either the collagen/epinephrine or the collagen/ADP channel has very
low positive predictive value (PPV) for AVWS, since such closure time prolongation
is also seen with thrombocytopenia, low haematocrit and acquired platelet function
defects.[63]
The latest version of MEA incorporates a RISTOtest, containing ristocetin for the
quantitative determination of vWF- and GPIb-dependent platelet aggregation, but is
available for research use only.
The performance of a modified TEG assay to screen for vWD was evaluated in 328 patients,
assessing the ratio of clot strength (MA) with and without pre-incubation of blood
with ristocetin. A decrease in MA with a cut-off of 25% for the AUC ratio resulted
in a sensitivity of 53 to 100% for different types of vWD.[64] The same group subsequently compared the performance of TEG and ROTEM in 100 patients
with vWD and 89 healthy controls.[65] Prolonged TEG R-time had a PPV of 0.84 and a NPV of 0.68 respectively, while the
clotting index (CI) had a PPV of 1.00 and an NPV of 0.60. Both R-time and CI had a
high specificity and accurately discriminated VWD patients from healthy controls,
with an AUC of 0.85 and 0.99, respectively. On the other hand, ROTEM parameters could
not differentiate patients with vWD from healthy controls.[65] However, a recent modification of the ROTEM assay with pre-incubation of the blood
sample with ristocetin and commercially available vWF has shown promise in identifying
vWD in a small study of 27 out-patients,[66] but there has been no further validation.
Quantification of vWF Cleavage
A relatively recent development is a mass spectrometry method to quantify vWF cleavage
as the ratio of the ADAMTS-13-cleaved peptide MVTGNPASDEIK to the ILAGPAGDSNVVK peptide.
While this has not been evaluated in ECMO patients, increased vWF cleavage was detected
in samples from patients on left ventricular assist devices who had developed bleeding.[67] However, this requires special laboratory expertise and is time-consuming, such
that it may not be practical for routine clinical use.
Global Thrombosis Test
This automated point-of-care test assesses the time taken to form an occlusive thrombus
under high shear stress (occlusion time), and in the subsequent phase of the test,
measures the time taken for spontaneous restart of flow, as a measure of endogenous
fibrinolysis (lysis time). It assesses native, non-anticoagulated whole blood and
is a global test of thrombosis. It has been shown to identify patients who are prothrombotic
due to impaired endogenous fibrinolysis, in the setting of acute coronary syndromes.[68]
[69] As it provides a global assessment of thrombotic status, including platelet reactivity
and coagulation in the setting of high shear, it would seem an ideal point-of-care
test in patients on ECMO. It could be used to assess the risk of thrombosis (short
occlusion time and/or long lysis time) and bleeding (long occlusion time and/or short
lysis), but studies to date have not been performed in this patient group.
Total Thrombus-Formation Analysis System
This is a relatively novel point-of-care flow chamber system which employs two microchips;
the platelet (PL) chip AUC assesses platelet function and primary haemostasis, while
the atheroma (AR) chip assesses overall haemostatic ability. It has been shown to
be of use in monitoring the effects of antiplatelet therapy and the severity of vWD
type 1, with small AUC predictive of peri-procedural bleeding in patients undergoing
stenting.[70] In four patients on continuous flow left ventricular assist devices, HMWM vWF and
Total Thrombus-formation Analysis System (T-TAS) PL24-AUC10 and AR10-AUC30 were significantly
reduced compared with anticoagulated control patients.[70] Future studies are required to see whether it could be used to detect AVWS in patients
on ECMO.
Growth Differentiation Factor-15
Growth differentiation factor-15 (GDF-15), a member of the transforming growth factor-β
superfamily, is upregulated in many disease states including cardiovascular disease,
has been shown to reduce ADP-induced platelet aggregation in a dose-dependent manner
and is a marker of bleeding. In large studies in patients on dual antiplatelet therapy
or oral anticoagulation, elevated GDF-15 levels were independently associated with
major bleeding during follow-up.[71]
[72] Circulating GDF-15 level has been shown to be elevated in patients with heart failure
prior to left ventricular assist device implantation, and to fall significantly after
1 month of mechanical unloading,[73] but there are no studies assessing its utility to predict bleeding in patients on
ECMO.
Possible Novel Anticoagulant Approaches
Possible Novel Anticoagulant Approaches
Exposure of blood to artificial surfaces potentiates thrombosis through contact activation, namely the activation of factor XII (FXII), XI (FXI) and plasma prekallikrein. Targeted
inhibition of FXIa or FXIIa may reduce thrombotic risk associated with contact activation,
while leaving haemostasis largely intact,[74] an avenue that seems particularly attractive in patients on ECMO who require anticoagulation
but are prone to excessive bleeding.
In rabbits connected to a paediatric ECMO circuit, a recombinant fully human FXIIa
activity-neutralising antibody (3F7) dose-dependently reduced thrombus formation at
arterial shear rates, without an increase in bleeding.[75] In primates, monoclonal antibodies against FXII reduced thrombosis in collagen-coated
arteriovenous grafts.[76] In rabbits, antisense oligonucleotides (ASOs) inhibiting the production of FXII
or FXI prolonged the time to catheter-induced venous thrombosis,[77] while a monoclonal immunoglobulin G against FXIa was as effective as rivaroxaban
in preventing venous thrombosis, without increasing cuticle bleeding.[78] It remains to be established if FXII or FXI is the better target for thromboprophylaxis
in patients supported by devices with artificial surfaces. While FXII inhibition may
not increase the risk of bleeding, inhibition of FXI may produce a more potent antithrombotic
effect. No clinical trials employing FXII inhibition in humans have been reported;
however, there are several different approaches being developed to inhibit FXI, including
ASOs, monoclonal antibodies, aptamers and small molecules. Small-molecule inhibitors
can be delivered orally or parenterally, whereas ASOs, antibodies and aptamers require
parenteral administration. Antibodies, aptamers and small molecules can achieve rapid
FXI inhibition while ASOs can take 3 to 4 weeks to achieve therapeutic anticoagulation.
In phase II trials in patients undergoing knee surgery, an ASO FXI inhibitor[79] administered subcutaneously and an anti-FXIa antibody osocimab,[80] given intravenously, have both been shown to be superior to enoxaparin for thromboprophylaxis
without an increase in bleeding.[79] A small-molecule oral FXIa inhibitor has commenced a phase IIb program (PACIFIC),
enrolling more than 4,000 patients with atrial fibrillation, myocardial infarction,
or stroke. Several ongoing phase II studies will assess the safety of FXI inhibition
in patients with end-stage renal disease on haemodialysis. There are no studies in
patients on MCS, although onset of effect, half-life and offset/reversibility will
be key issues when considering such strategies in patients on ECMO.
Guide to Haemostasis Assessment and Management
Guide to Haemostasis Assessment and Management
We provide a summary and schematic for assessing thrombosis and bleeding risk in patients
on ECMO ([Fig. 2]), based on our experience combined with literature review. Anti-Xa level best correlates
with heparin dose, and appears predictive of thrombosis, although aPTT may be a better
predictor of bleeding. In the absence of data to guide optimal anticoagulation, the
2014 ELSO anticoagulation guideline states that the majority of ELSO centres that
use the anti-Xa levels aim for a target of 0.3 to 0.7 IU/mL, which is a very broad
range.[13] We use the lower end of the range, aiming for 0.2 to 0.5 IU/mL to reduce the risk
of bleeding, with a lower target of 0.2 to 0.3 IU/mL for patients on VV ECMO, based
on our experience[45] and supported by a protocol in the EOLIA trial.[81] HR should be considered in patients who are not achieving the desired anti-Xa level
despite escalating doses of UFH. In such cases, the AT level should be checked and
preferably maintained in the normal range, with consideration given to switching from
UFH to a direct thrombin inhibitor such as argatroban. Patients with thrombocytopenia
or those who are bleeding should be promptly investigated for HIT, with consideration
of alternative anticoagulation. The patient should be assessed for AVWS and ECMO flow
rates should be adjusted to minimise AVWS whenever possible. Viscoelastic tests may
be used to assess bleeding risk. Platelet aggregation should be assessed relative
to platelet count, and in patients experiencing major bleeding with markedly impaired
platelet aggregation on antiplatelet medication, consideration should be given to
the risks and benefits of withholding antiplatelet medication as indicated by the
clinical scenario (such as in the case of acute coronary syndrome, recent stent implantation
in a major artery or last remaining conduit) in consultation with the wider clinical
team(s). In addition, platelet transfusion should be considered, even in the presence
of normal platelet count. If the ischaemic risk is high, antiplatelet therapy should
be continued and tranexamic acid administered concomitantly for 1 to 2 days. In patients
experiencing thrombosis, anti-Xa levels and possibly TG may be useful, where rising
ETP may indicate a risk of venous thrombosis.
Fig. 2 Proposal for monitoring patients on mechanical circulatory support (MCS). Baseline
assessment and monitoring of anticoagulation is required in all patients as shown.
Patients on MCS are at risk of both thrombosis (green panels) and bleeding (red panels), requiring regular assessment (turquoise panels). To prevent bleeding while preventing thrombosis, we aim to keep heparin anti-Xa
level in the target 0.2–0.5 IU/mL, at the lower end of the therapeutic range. Patients
on MCS are at risk of developing platelet dysfunction due to loss of platelet receptors
and AVWS despite normal platelet count. Platelet function tests allow the identification
of these patients and if the patient is bleeding despite normal coagulation assays
and platelet count, assessment of platelet function can help reveal platelet dysfunction.
In patients with recurrent thrombotic events, particularly arterial events, despite
adequate anticoagulation, and normal or activated platelet response, the addition
of antiplatelet treatment to anticoagulation can be considered. [*] Dose range is given to reflect the variation in practice. anti-PF4, anti-platelet
factor 4 antibodies; aPTT, activated partial thromboplastin time; AT, antithrombin;
AVWS, acquired von Willebrand syndrome; CRP, C-reactive protein; CT, computed tomography;
DIC, disseminated intravascular coagulation; ELISA, enzyme-linked immunosorbent assay;
HIT, heparin-induced thrombocytopenia; ICH, intracranial haemorrhage; LTA, light transmittance
aggregometry; MEA, multiple electrode aggregometry; pf-Hb, plasma-free haemoglobin;
PT, prothrombin time; ROTEM, rotational thromboelastometry; t.d.s., ter die sumendum
(3 times a day); TEG, thromboelastography; UFH, unfractionated heparin.
Discussion
There are no prospective randomised controlled studies assessing clinical outcomes
in patients on ECMO receiving UFH which compare monitoring with aPTT versus heparin
anti-Xa level, to guide recommendations for anticoagulant monitoring. Measurement
of anti-Xa level best correlates with heparin dose, and appears predictive of thrombosis,
although the aPTT level is a better predictor of bleeding. Platelets play a major
role in both primary and secondary haemostasis. In addition to thrombocytopenia due
to reduced bone marrow production, sepsis, pooling of platelets in the liver or spleen,
and consumption of platelets through the MCS, there is also a high risk of platelet
dysfunction which is directly related to the degree of shear and the duration of exposure
to the artificial circuit. The high shear in MCS appears to cause vWF binding on the
platelet surface and increasing the propensity for bleeding. AVWS, best detected by
assessing the vWF:RCo ratio, is frequent, almost universal in patients on MCS, contributing
to bleeding. Tests of platelet aggregation may be additionally used to predict bleeding.
High shear stress also causes platelet activation and simultaneously increases the
risk of thrombosis. Despite conventional monitoring of UFH, there is a high rate of
thrombotic and bleeding complications with MCS. A selection of complementary tests
to collectively assess heparin effect, coagulation, platelet function and platelet
aggregation would be most useful for optimal early detection of bleeding and thrombosis
risk, to personalise management and optimise outcomes in patients on MCS.
What is known about this topic?
What does this paper add?
-
We describe the selection of complementary tests which can collectively assess heparin
effect, coagulation, platelet function and platelet aggregation, with supporting evidence
in ECMO, to enable personalised management and optimise outcomes.
1. Literature search strategy
The literature search was performed by searching the MEDLINE/PubMed database, combining
the search terms (‘extracorporeal membrane oxygenation’ OR ‘ECMO’ OR ‘mechanical circulatory
support’) AND the terms (‘heparin’ OR ‘anticoagulation’ OR ‘anticoagulant’ OR ‘ACT’
OR ‘APTT’ OR ‘anti-Factor X level’ OR ‘Antithrombin III’ OR ‘von Willebrand syndrome’
or ‘von Willebrand factor’ OR ‘TEG’ OR ‘ROTEM’ OR ‘platelet function’ OR ‘multiplate’
OR ‘MEA’ OR ‘thrombin generation’ OR ‘endogenous thrombin potential’ OR ‘platelet
aggregation’ OR ‘light transmittance aggregometry’ OR ‘PFA’ OR ‘VerifyNow’ OR ‘Global
Thrombosis Test’ OR ‘T-TAS’ OR ‘GDF-15’ OR ‘Biomarkers of bleeding’ OR ‘Biomarkers
of thrombosis’) in any combination. Articles were filtered based on title and abstract,
and reference lists were traced to identify additional articles of relevance. We included
case series, observational or interventional studies and review articles, but excluded
isolated case reports. There were no language restrictions.
